Status:
COMPLETED
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Thrombosis, Venous
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Hormone refractory prostate cancer within 6 months of diagnosis, OR locally advanced (non-metastasized) pancreatic cancer within 3 months of diagnosis, OR non-small-cell lung cancer within 3 months of stage IIIB.
- Exclusion criteria:
- Life expectancy of \<3 months.
- Poor performance status (Karnofsky \<60).
- Need to be on anticoagulants.
- Use of nadroparin (a low molecular weight heparin) for any reason including a history of heparin-induced thrombocytopenia.
- Have brain metastasis.
- At a high risk of bleeding or have a platelet count \<50,000/mm3.
- Have very poor kidney function.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
503 Patients enrolled
Trial Details
Trial ID
NCT00312013
Start Date
May 1 2006
End Date
July 1 2009
Last Update
March 23 2017
Active Locations (95)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Aalst, Belgium, 9300
2
GSK Investigational Site
Antwerp, Belgium, 2020
3
GSK Investigational Site
Brasschaat, Belgium, 2930
4
GSK Investigational Site
Brussels, Belgium, 1070